- Home
- IMTX
IMTX
Immatics N.V.
as 07-26-2024 4:00pm EST
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
| Founded: | N/A | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $16.00 | AVG Volume (30 days): | 304.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.15 - $13.77 | Next Earning Date: | 08-15-2024 |
| Revenue: | $80,945,652 | Revenue Growth: | -6.58% |
| Revenue Growth (this year): | 29.86% | Revenue Growth (next year): | -14.39% |
Latest Immatics N.V. News
IMTX Breaking Stock News: Dive into IMTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years
GlobeNewswire
8 days ago
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Simply Wall St.
a month ago
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare IMTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMTX Immatics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.